|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
Esophagitis, erosive |
|
Gastroesophageal Reflux Disease |
|
Mastocytosis, systemic |
|
Ulcer, duodenal |
|
Ulcer, gastric |
|
Zollinger- Ellison syndrome |
| |
|
|
SIDE EFFECTS:
|
|
abdominal pain |
|
agitation |
|
agranulocytosis |
|
alopecia |
|
anaphylactoid reactions |
|
angioedema |
|
aplastic anemia |
|
arthralgia |
|
AV block |
|
blurred vision |
|
bronchospasm |
|
confusion |
|
constipation |
|
delirium |
|
depression |
|
diarrhea |
|
dizziness |
|
elevated hepatic enzymes |
|
eosinophilia |
|
erythema multiforme |
|
gynecomastia |
|
hallucinations |
|
headache |
|
hemolytic anemia |
|
hepatitis |
|
impotence |
|
insomnia |
|
jaundice |
|
leukopenia |
|
libido decrease |
|
maculopapular rash |
|
myalgia |
|
nausea/vomiting |
|
neutropenia |
|
pancreatitis |
|
pancytopenia |
|
paranoia |
|
premature ventricular contractions (PVCs) |
|
sinus bradycardia |
|
sinus tachycardia |
|
Stevens-Johnson syndrome |
|
thrombocytopenia |
|
toxic epidermal necrolysis |
|
vasculitis |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
breast-feeding |
|
children |
|
elderly |
|
gastric cancer |
|
2-blocker*hypersensitivity#243"H2-blocker hypersensitivity |
|
infants |
|
infection |
|
neonatal prematurity |
|
neonates |
|
phenylketonuria |
|
porphyria |
|
pregnancy |
|
renal disease |
|
renal failure |
|
renal impairment |
|
|
ADULT DOSE:
|
|
Duodenal ulcer or
Gastric ulcer or
Gastric hypersecretory conditions (e.g., Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas) and
[Prophylaxis of stress-related mucosal bleeding]-Intramuscular, 50 mg every six to eight hours.
Intravenous, 50 mg every six to eight hours, diluted to a total volume of 20 mL with a compatible intravenous solution and administered over a period of not less than five minutes.
Intravenous infusion, 50 mg every six to eight hours, diluted in 100 mL of a compatible intravenous solution and administered over a fifteen- to twenty-minute period.
Continuous intravenous infusion, 6.25 mg per hour, diluted in a compatible intravenous solution.
Note: For gastric hypersecretory conditions, the infusion should be started at 1 mg per kg of body weight per hour and increased by 0.5 mg per kg of body weight per hour increments (if gastric acid output is greater than 10 mEq per hour or patient is symptomatic), up to 2.5 mg per kg of body weight per hour.
[Prophylaxis of aspiration pneumonitis]-Intramuscular or slow intravenous injection, 50 mg administered forty-five to sixty minutes before induction of general anesthesia.
Note: For patients with impaired renal function (creatinine clearance of less than 50 mL per minute)-Intravenous, 50 mg every eighteen to twenty-four hours, the frequency of the dosage being increased to every twelve hours or more frequently, if necessary. Further reduction in dosage may be required if hepatic function impairment is also present. |
|
MAXIMUM ADULT DOSE:
|
|
400 mg a day.
|
|
PEDIATRIC DOSE:
|
|
Duodenal ulcer or
Gastric ulcer-Intravenous infusion, 2 to 4 mg per kilogram of body weight a day , diluted to a suitable volume with a compatible intravenous solution and administered over a fifteen- to twenty-minute period
Gastroesophageal reflux-Intravenous infusion, 2 to 8 mg per kg of body weight, diluted in a suitable volume with a compatible intravenous solution and administered over a fifteen- to twenty-minute period, three times a day.
Note: In certain circumstances, doses may be titrated based on gastric pH. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
Duodenal ulcer or
Gastric ulcer or
Gastric hypersecretory conditions (e.g., Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas) and
[Prophylaxis of stress-related mucosal bleeding]-Intramuscular, 50 mg every six to eight hours.
Intravenous, 50 mg every six to eight hours, diluted to a total volume of 20 mL with a compatible intravenous solution and administered over a period of not less than five minutes.
Intravenous infusion, 50 mg every six to eight hours, diluted in 100 mL of a compatible intravenous solution and administered over a fifteen- to twenty-minute period.
Continuous intravenous infusion, 6.25 mg per hour, diluted in a compatible intravenous solution.
Note: For gastric hypersecretory conditions, the infusion should be started at 1 mg per kg of body weight per hour and increased by 0.5 mg per kg of body weight per hour increments (if gastric acid output is greater than 10 mEq per hour or patient is symptomatic), up to 2.5 mg per kg of body weight per hour.
[Prophylaxis of aspiration pneumonitis]-Intramuscular or slow intravenous injection, 50 mg administered forty-five to sixty minutes before induction of general anesthesia.
Note: For patients with impaired renal function (creatinine clearance of less than 50 mL per minute)-Intravenous, 50 mg every eighteen to twenty-four hours, the frequency of the dosage being increased to every twelve hours or more frequently, if necessary. Further reduction in dosage may be required if hepatic function impairment is also present. |
|
|
|
|
|